8-K: Pasithea Therapeutics Boosts Share Authorization, Stock Plan

Pasithea Therapeutics Corp. stockholders approved significant increases in authorized common stock and shares available under its 2023 Stock Incentive Plan.

Summary

• Stockholders approved an amendment to the Certificate of Incorporation, increasing the company's authorized common stock from 100,000,000 shares to 500,000,000 shares.
• The total authorized capital stock is now 505,000,000 shares, comprising 500,000,000 common shares and 5,000,000 preferred shares.
• Stockholders also approved an amendment to the 2023 Stock Incentive Plan, increasing the maximum aggregate number of shares authorized for issuance by 11,985,779 shares, bringing the new total to 14,000,000 shares.
• Both proposals were approved at a Special Meeting of Stockholders held on January 28, 2026.
• Proposal 1 (increase in authorized common stock) was approved with 16,066,757 'FOR' votes, 647,972 'AGAINST' votes, and 31,532 'ABSTAIN' votes.
• Proposal 2 (increase in stock incentive plan shares) was approved with 8,168,126 'FOR' votes, 4,550,855 'AGAINST' votes, 5,569 'ABSTAIN' votes, and 4,021,711 'BROKER NON-VOTES'.
• A quorum was present at the Special Meeting, with 16,746,261 shares represented out of 23,091,062 shares outstanding and entitled to vote.

Sentiment

Score: 6

Explanation: While the potential for dilution exists, the approvals provide the company with crucial flexibility for future growth, capital raising, and talent retention, which are generally positive for long-term strategic positioning.

Positives

• Increased flexibility for the company to raise capital through equity offerings in the future, supporting potential growth initiatives.
• Expanded pool of shares for the 2023 Stock Incentive Plan allows for greater ability to attract, retain, and incentivize employees, directors, and consultants with equity compensation.
• Stockholder approval of these proposals demonstrates support for management's strategic initiatives and long-term planning.

Negatives

• The significant increase in authorized common stock from 100,000,000 to 500,000,000 shares creates potential for substantial future shareholder dilution if new shares are issued.
• The increase in the stock incentive plan also contributes to potential future dilution for existing shareholders.

Risks

• Shareholder Dilution: The substantial increase in authorized common stock from 100,000,000 to 500,000,000 shares, and the increase in the 2023 Stock Incentive Plan by 11,985,779 shares to 14,000,000 shares, creates a significant risk of future dilution for current shareholders if these shares are issued.
• Market Perception: The market may react negatively to the potential for significant dilution, impacting the company's stock price.

Future Outlook

The company now has significantly increased capacity to issue common stock, providing strategic flexibility for future capital raises, mergers and acquisitions, or other corporate purposes. The expanded stock incentive plan also enhances the company's ability to use equity-based compensation to attract and retain talent.

Management Comments

• Tiago Reis Marques, Chief Executive Officer, signed the Certificate of Amendment and the 8-K filing, indicating management's endorsement of these corporate actions.

Industry Context

Companies, particularly in sectors like biotechnology or pharmaceuticals, often require substantial capital for research, development, and commercialization. Increasing authorized shares is a common preparatory step for future equity financing rounds. Stock incentive plans are also standard tools for attracting and retaining talent in competitive industries.

Corporate Governance

Stakeholder Impact

• Shareholders: Face potential future dilution due to the significant increase in authorized shares, which could impact per-share value. However, the increased flexibility for capital raises could support long-term growth initiatives.
• Employees/Management: Benefit from an expanded stock incentive plan, allowing for more equity-based compensation, which can enhance motivation and retention.

Next Steps

• The company will proceed with the implementation of the approved amendments to its Certificate of Incorporation and the 2023 Stock Incentive Plan.

Key Dates

Keywords

authorized shares, stock incentive plan, equity financing, shareholder dilution, corporate governance, common stock, stock options, capital raise, Pasithea Therapeutics